AC
UTHR icon

AXQ Capital’s United Therapeutics UTHR Stock Holding History

AXQ Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,888
Closed -$1.12M – 839
2025
Q2 		$1.12M Buy
3,888
+3,235
+495% +$967K 0.36% 65
2025
Q1 		$201K Sell
653
-634
-49% -$217K 0.08% 395
2024
Q4 		$454K Buy
+1,287
New +$473K 0.2% 186
2024
Q2 		– Sell
-2,006
Closed -$461K – 747
2024
Q1 		$461K Sell
2,006
-3,800
-65% -$858K 0.11% 322
2023
Q4 		$1.28M Buy
5,806
+2,500
+76% +$576K 0.34% 68
2023
Q3 		$747K Buy
3,306
+2,206
+201% +$508K 0.26% 142
2023
Q2 		$243K Buy
+1,100
New +$244K 0.3% 161

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AXQ Capital's UTHR Position: Q3 2025 in Review

AXQ Capital sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 3,888 shares — an estimated $1.12M sold.

AXQ Capital first reported a position in UTHR in Q2 2023 and held it in 7 quarters. The position peaked at $1.28M in Q4 2023. 708 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • AXQ Capital reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AXQ Capital sold 3,888 United Therapeutics shares in Q3 2025, an estimated $1.12M.
  • AXQ Capital first reported a position in United Therapeutics in Q2 2023 and held it in 7 quarters.
  • AXQ Capital's United Therapeutics position peaked at $1.28M in Q4 2023.
  • 708 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.